Key Highlights

  • Anthropic (NASDAQ:ANT) plans to sell 825 million shares at USD 70 to USD 78 each, with pricing expected on November 18, 2026 and trading the following day.
  • Orders have reportedly reached close to seven times the shares on offer, yet a poll found 67% of 18,100 retail traders do not plan to buy at the IPO price.
  • Forge Nano fell 16.59% on November 16 after its first results as a listed company reiterated a 2026 outlook below an earlier target.
  • TRexBio fell 21.21% after a wider third quarter loss, showing how hard recent listings can fall in a risk-off market.

1. TRexBio (NASDAQ:TRXB)

TRexBio (NASDAQ:TRXB) carries the most risk of the three. The immunology company priced its IPO in October at USD 14.00 per share, selling 9,539,237 shares to raise about USD 133.5 million gross and USD 119.0 million net. On November 16 it fell 21.21%, the steepest decline among notable movers that day, after a third quarter report released on November 13 showed a net loss of USD 13.2 million, compared with USD 7.9 million a year earlier. Research and Development spending rose to USD 11.4 million from USD 7.0 million. The company had USD 78.2 million in cash and marketable securities on September 30, excluding IPO proceeds, and says its resources fund operations into the second half of 2029. Nothing in the report was alarming, which suggests the decline reflected selling by IPO buyers as much as the numbers. The risk lies in the clinical path. Its lead candidate, a TNFR2 agonist designed to activate regulatory T cells, is in a mid-stage atopic dermatitis study with topline results expected in mid-2027, and its second candidate is expected to enter a Phase 1 trial in the first half of 2027. Until then, the shares lack near-term catalysts, and a lock-up expiry about six months after listing is another overhang.

2. Forge Nano (NASDAQ:NANO)

Forge Nano (NASDAQ:NANO) fell 16.59% on November 16 after its first Quarterly Report as a listed company. It supplies atomic layer deposition technology, a method of applying coatings a few atoms thick, used in semiconductor equipment and battery materials. It began trading on October 22, 2026 after combining with a special purpose Acquisition company, raising more than USD 130 million in gross proceeds, including a USD 123 million private Placement and about USD 8.4 million left in the trust after redemptions. Management reiterated its 2026 outlook of about USD 18 million of revenue, USD 12.7 million of government grant income and USD 9.4 million of HZO Revenue on a full-year basis, after closing the all-stock purchase of the coatings Business on November 4. The combined figure is well below the roughly USD 40 million target set in April 2026, a gap that likely weighed on sentiment because investors had anchored to the earlier number. The longer-term case rests on a battery-materials factory in North Carolina planned to start production in 2028, backed by a federal cost-share grant of up to USD 100 million. Those projects require Capital and execution, so orders, grant disbursements and margins will drive the stock. It ranks second for risk because its revenue base is real but small.

3. Anthropic (NASDAQ:ANT)

Anthropic (NASDAQ:ANT) carries the least Business Risk of the three but the most valuation risk. The company plans to sell 825 million shares at USD 70 to USD 78 each, raising up to about USD 64.4 billion, with pricing expected on November 18 and trading on Nasdaq the following day. Seven computing suppliers, including Alphabet, Microsoft and Nvidia, have agreed to buy USD 26 billion of shares at the IPO price, so the total raise could reach about USD 90.4 billion, the largest listing on record. Institutional Demand is strong, with orders reportedly close to seven times the shares on offer, and a large growth investor said it placed a USD 5 billion order and expects a valuation of about USD 1.4 trillion to USD 1.5 trillion. Retail traders are cooler. In a poll of 18,100 respondents, 67% said they would not buy at the IPO price, 20% said they would and 13% were waiting for the final price. The company's filings show third quarter revenue of USD 17 billion, about twelve times a year earlier, an operating loss of USD 567 million and compute commitments of USD 900.9 billion. Pricing above the range would leave less room for gains after listing. This piece was written before pricing, so terms may change.

Where Things Stand

Of the top 3 IPO stocks in focus this week, TRexBio carries the most risk, with a wider loss and clinical results not due until mid-2027. Forge Nano faces a gap between its outlook and earlier targets, while Anthropic offers strong growth and demand but a valuation of around USD 1.4 trillion. Anthropic's pricing on November 18 and first day of trading will set the tone for new listings into 2027.